PCR–ELISA for High-Throughput Blood Group Genotyping
During the last decade, blood bank specialists have shown an increased interest in molecular analyses to complement serology work in determining blood group antigens. To efficiently respond to the numerous demands made for hemolytic disease of the newborn cases and polytransfused patients, we designed an inexpensive colorimetric high-throughput method to genotype several blood group antigens rapidly. Three simple steps are required to perform this technique: genomic DNA extraction, PCR amplification, and amplicon detection by a microplate ELISA. The 96-well plate format facilitates the manipulations and enables the analysis of multiple samples at once or the analysis of multiple antigens for fewer samples.
The most common and clinically relevant minor blood group antigens were adapted to this method and are described in this work: Rh (D, C, c, E, e), Kell (K, k), Duffy (Fya, Fyb), and Kidd (Jka, Jkb). Other blood group antigens could be easily tested this way as long as their molecular basis is well established.
Key WordsBlood groups genotyping PCR–ELISA microplate biotin DIG
The author would like to thank Jos’ee Perreault for her technical support and for reviewing the manuscript.
- 3.Kim, J. -W., Shim, J. -H., Park, J. -W., Jang, W. -C., Chang, H. K., Song, I. H., Baek, S. -Y., Lee, S. -H., Yoon, D. -Y., Park, S. -N. (2005) Development of PCR–ELISA for the detection of hepatitis B virus x gene expression and clinical application. J Clin Lab Anal 19,139–145.CrossRefPubMedGoogle Scholar
- 7.Rapier, J. M., Villamarzo, Y., Schochetman, G., Ou, C. -Y., Brakel, C. L., Donegan, J., Maltzman, W., Lee, S., Kirtikar, D., Gatica, D. (1993) Nonradioactive, colorimetric microplate hybridization assay for detecting amplified human immunodeficiency virus DNA. Clin Chem 39, 244–247.PubMedGoogle Scholar
- 9.St-Louis, M., Thibault, L., Chevrier, M.-C., Perreault, J., Richard, M., de Grandmont, M. J., Beauséjour, A., Nolin, M., Guérin, M., Vachon, A., Lemieux, R. (2003) In-house development and production of a WNV NAT assay for possible contingency testing of blood donors in June 2003. Transfusion 43, 128A (meeting abstract).CrossRefGoogle Scholar